Welcome to our dedicated page for Cvs Health news (Ticker: CVS), a resource for investors and traders seeking the latest updates and insights on Cvs Health stock.
CVS Health Corporation operates an integrated health care model that combines retail pharmacy, pharmacy benefit management, health insurance, medical clinics, specialty and mail pharmacy support, and related consumer health services. Recurring company news includes quarterly results and guidance, segment performance across Health Services, Health Care Benefits, and Pharmacy & Consumer Wellness, and capital returns through common-stock dividends.
Updates also cover CVS Caremark formulary decisions, biosimilar adoption, Aetna prior authorization and plan-administration initiatives, community health investments by the CVS Health Foundation, and developments involving Omnicare, the company's long-term care pharmacy subsidiary.
CVS Health (NYSE:CVS) announced initiatives to simplify care and lower costs, highlighting Aetna prior-authorization reforms, broader access programs, and pharmacy savings. Key metrics: approves >95% of eligible prior authorizations within 24 hours, 77% of electronic prior authorizations completed in real time (target >80% by year-end), prior-authorization bundling across cancer, musculoskeletal and IVF pathways, and embedding nurses in 17 major health systems to cut 30-day readmissions and length of stay by 5%. Pharmacy actions include a Humira alternative that generated $1.3B client savings and Caremark delivering rebate savings at the counter for 25M members.
CVS Health (NYSE: CVS) will hold a conference call with analysts and investors on Tuesday, February 10, 2026 at 8:00 a.m. ET to discuss fourth quarter and full year 2025 financial results. An audio webcast will be available live and archived for one year on the company's Investor Relations website at investors.cvshealth.com.
CVS (NYSE:CVS) announced a $2.6 million grant from the CVS Health Foundation to the American Diabetes Association to expand a maternal diabetes program into two additional New York City communities on Jan 14, 2026.
The expansion builds on 18 months of work that improved early gestational diabetes screening and care coordination for hundreds of patients at Wyckoff Heights Medical Center. Over the next three years the program will scale EMR dashboards, increase access to continuous glucose monitoring and medically tailored meals, deliver multilingual education, and track patients from pregnancy through postpartum to measure outcomes.
CVS Health (NYSE: CVS) will hold a conference call for fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026 at 8:00 a.m. ET.
An audio webcast will be broadcast simultaneously on the company's Investor Relations website at investors.cvshealth.com and will be archived there for one year.
CVS (NYSE: CVS) announced that its board approved a quarterly dividend of $0.665 per share on common stock.
The dividend is payable on February 2, 2026 to holders of record as of January 22, 2026.
CVS (NYSE:CVS) announced on Dec 11, 2025 that it is offering the measles-mumps-rubella (MMR) vaccine to South Carolina residents amid the state's current measles outbreak. More than 200 CVS Pharmacy and MinuteClinic locations across South Carolina will provide MMR vaccinations for patients ages 3 and older; MinuteClinic also provides the recommended second dose for children ages 4–6.
The MMR vaccine may provide some protection if given within 72 hours of exposure. Walk-ins are accepted at pharmacies, but appointments are encouraged via CVS.com, the CVS Health app, or MinuteClinic.com. Pharmacy and clinic staff can help check insurance coverage and determine immunity status.
CVS Health (NYSE: CVS) updated 2025 guidance, provided 2026 guidance, and outlined a multi-year growth plan at its 2025 Investor Day on Dec 9, 2025. The company raised 2025 revenue guidance to at least $400.0B, raised adjusted operating income guidance to $14.22B–$14.39B, and confirmed 2025 cash flow from operations of $7.5B–$8.0B. CVS initiated 2026 guidance with revenue of at least $400.0B, adjusted operating income of $15.07B–$15.41B, adjusted EPS of $7.00–$7.20, and at least $10.0B cash flow from operations.
The company expects a mid‑teens adjusted EPS CAGR through 2028, announced an AI‑native open consumer engagement platform, and reiterated strategic focus across Aetna, CVS Caremark, CVS Pharmacy, and Health Care Delivery.
CVS (NYSE: CVS) released its inaugural National Economic Impact Report on Dec 5, 2025, saying its operations deliver an annual $474 billion economic impact across the U.S. and support 1.3 million jobs nationwide.
The report cites 300,000+ employees, approximately 9,000 retail pharmacy locations and >1,000 walk-in and primary care clinics, serving 185 million individuals and placing nearly 85% of Americans within 10 miles of a CVS pharmacy.
Other metrics include $58.6 billion in local, state and federal taxes, $239 million in community investments, and 84,000 volunteer hours. The report uses IMPLAN-based analysis by Parker Strategy Group.
Aetna (NYSE: CVS) announced December 4, 2025 updates that simplify prior authorization, expand clinical collaboration, and add AI capabilities to the Aetna Health app.
Key actions: effective November 2025 Aetna now bundles medical and pharmacy prior authorizations for certain conditions (examples: IVF, musculoskeletal bundles including X-rays, THA/TKA, specified meds and DME). The Aetna Clinical Collaboration (ACC) program is live in 17 hospitals and is projected to reduce 30-day readmissions and length of stay by 5% when fully implemented. As part of CVS Health's $20 billion multi-year digital investment, generative AI features have launched to an initial population and will expand in early 2026.
Cornerstone Community Development, together with Winterwood and CVS Health (NYSE: CVS), will host the Prichard Centennial Residential Reveal & Next-Phase Preview on December 4, 2025 at 1:30 p.m. in Huntington, WV.
The event showcases newly completed residential spaces inside the historic Prichard building and previews the next restoration phase. CVS Health has invested more than $17 million in the Prichard adaptive-reuse and has invested over $21 million in affordable housing across West Virginia, helping create or preserve 800+ affordable units.